Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04608175
Other study ID # 001
Secondary ID 2019/59-FIS-HUSC
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2020
Est. completion date March 2023

Study information

Verified date September 2020
Source University Ramon Llull
Contact Carles Fernández, Phusical Terapist
Phone 0034651503494
Email carlesfj@blanquerna.url.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Breast cancer is one of the most prevalent cancers worldwide. Fortunately, survival has improved in recent years thanks to its early detection and curative treatments such as mastectomy. However, this medical procedure is associated with a range of unwanted effects such as postoperative pain and anxiety. Some studies have reported that acupuncture could be an effective treatment to control these types of symptoms, although only few studies have been conducted on women undergoing mastectomy. Methods: This is a pragmatic randomized controlled trial with blind assessors. The study will be conducted in the Breast Unit of Hospital Universitario Sagrado Corazon of Barcelona (Spain). A sample of 40 women will be recruited and randomized to receive acupuncture treatment in addition to standard care procedures, or standard care procedures alone. The main outcome, pain, will be assessed after the surgical intervention and 4, 10 and 30 days later using the numerical rating scale. Secondary outcomes include anxiety, use of analgesics, nausea, adverse effects, and surgical complications. Discussion: Acupuncture is a low-cost non-pharmacological strategy. This study will help to clarify its possible role in controlling post-mastectomy adverse effects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date March 2023
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - Diagnosis of breast cancer - Primary breast cancer patient - Candidate for breast cancer surgery (mastectomy) - Aged between 20 and 70 years old - Consenting to participate in the study and signing the informed consent form. Exclusion Criteria: - Have a previous history of breast cancer - Have a previous diagnosis of a severe psychiatric disorder - Present risk factors associated with breast cancer - Do not speak Spanish or Catalan - Are currently participating in another trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acupuncture
Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University Ramon Llull Hospital Quiron Sagrado Corazon

Outcome

Type Measure Description Time frame Safety issue
Primary Post-intervention pain at 12 hours after surgery Pain will be evaluated using the numerical rating scale (NRS). This measure uses a scale of 0 to 10 in which the higher values represent the most severe pain. 12 hours after surgery (before the acupuncture treatment)
Primary Post-intervention pain at 48 hours after surgery Pain will be evaluated using the numerical rating scale (NRS). This measure uses a scale of 0 to 10 in which the higher values represent the most severe pain. 48 hours after surgery (after the acupuncture treatment)
Primary Post-intervention pain at first out-patient visit Pain will be evaluated using the numerical rating scale (NRS). This measure uses a scale of 0 to 10 in which the higher values represent the most severe pain. In the first out-patient visit between 10 and 12 days after the intervention (evaluated before the acupuncture session)
Primary Analgesic compsumption during hospital stay Amount of analgesic medication administered (ex: mg) During the hospital stay
Primary Analgesic compsumption at home Amount of analgesic medication administered (ex: mg) From discharge until day 15 after surgery.
Secondary Anxiety at 12 hours Anxiety will be evaluated by the Spanish version of the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). This scale has a score between 0 and 21 for either anxiety or depression with greater punctuation indicating a worse condition. Evaluations will be made 12 hours after the intervention
Secondary Anxiety at 48 hours Anxiety will be evaluated by the Spanish version of the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). This scale has a score between 0 and 21 for either anxiety or depression with greater punctuation indicating a worse condition. Evaluations will be made 48 hours after the intervention
Secondary Anxiety at first visit Anxiety will be evaluated by the Spanish version of the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). This scale has a score between 0 and 21 for either anxiety or depression with greater punctuation indicating a worse condition Evaluations will be made at first visit, between 10 and 12 days after the intervention.
Secondary Anxiety at one month Anxiety will be evaluated by the Spanish version of the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). This scale has a score between 0 and 21 for either anxiety or depression with greater punctuation indicating a worse condition. Evaluations will be made at one month after surgery.
Secondary Postoperative nausea after surgery The intensity of postoperative nausea will also be evaluated by the numerical rating scale (NRS) At 12 hours after surgery
Secondary Postoperative nausea at 24-48 hours The intensity of postoperative nausea will also be evaluated by the numerical rating scale (NRS) At 24-48 hours after surgery
Secondary Post-operative complications Post-operative complications such as seroma, infection and wound healing will be recorded. Up to one month.
Secondary Acupuncture adverse events Adverse events possibly linked to acupuncture such as pain, hematomas etc. will be recorded. Up to one month.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Active, not recruiting NCT03664778 - Abbreviated Breast MRI After Cancer Treatment
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Active, not recruiting NCT04568902 - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Phase 1
Completed NCT02860585 - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation N/A
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT03698942 - Delphinus SoftVueâ„¢ ROC Reader Study
Completed NCT00092950 - Exercise in Women at Risk for Breast Cancer Phase 2
Withdrawn NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Not yet recruiting NCT02151071 - The Breast Surgery EnLight and LightPath Imaging System Study Phase 1/Phase 2
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02931552 - Nuevo Amanecer II: Translating a Stress Management Program for Latinas N/A
Recruiting NCT02547545 - Breast Cancer Chemotherapy Risk Prediction Mathematical Model N/A
Completed NCT02303366 - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 Phase 1
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02518477 - Preventive Intervention Against Lymphedema After Breast Cancer Surgery N/A